Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with LIBERTYTM Robotic System
January 14 2021 - 7:00AM
The continued progression of Microbot Medical Inc.’s (Nasdaq: MBOT)
LIBERTY™ Robotic System was further demonstrated as the
Company announced the successful completion of an additional
feasibility animal study using the world’s first fully disposable
surgical robotic system. The study end points included navigating
to a clot, crossing the clot, deploying a stent retriever, and
manually retrieving an arterial clot in a live pig. All the end
points were met with no intraoperative adverse events. The animal
feasibility studies to date, support the Company’s assertion that
LIBERTY will potentially allow physicians to safely and easily
conduct catheter-based peripheral and neurovascular procedures
remotely, avoiding radiation exposure, physical strain and the risk
of cross contamination.
“As we continue to evaluate LIBERTY in the hands
of leading clinicians, the system is performing to our expectations
and achieving the desired clinical and usability outcomes,”
commented Harel Gadot, Chief Executive Officer, President, and
Chairman. “Additional studies are planned throughout the coming
year to allow us to achieve our regulatory goals.”
The procedure was performed by Dr. Gal Yaniv, a
recently added member of the Company’s Scientific Advisory Board
(SAB), who also serves as Director of Endovascular Neurosurgery at
Sheba Tel HaShomer City of Health and Chief Medical Officer of
Aidoc Medical, a full body imaging AI software firm. Dr. Yaniv
conducted the procedure and the results demonstrated robust
navigation capabilities and intuitive usability.
Mr. Gadot will be presenting an overview of the
Company later today at 2:00pm ET. The live and archived replays of
the presentation may be accessed via the ‘Investors’ section, under
‘Presentation + Resources’ of the Company’s website at
www.microbotmedical.com.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, focused primarily on
both natural and artificial lumens within the human body.
Microbot’s current proprietary technological platforms provide the
foundation for the development of a Multi Generation Pipeline
Portfolio (MGPP).
Microbot Medical was founded in 2010 by Harel
Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of
improving clinical outcomes for patients and increasing
accessibility through the use of micro-robotic technologies.
Further information about Microbot Medical is available at
http://www.microbotmedical.com.
Safe Harbor
Statements pertaining to the registered direct
offering, timing, the amount and anticipated use of proceeds and
statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for Microbot Medical Inc. and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions and
the satisfaction of customary closing conditions, risks inherent in
the development and/or commercialization of potential products,
including LIBERTY™ and SCS, the outcome of its studies to
evaluate LIBERTY, SCS and other existing and future technologies,
uncertainty in the results of pre-clinical and clinical trials or
regulatory pathways and regulatory approvals, uncertainty resulting
from the COVID-19 pandemic, need and ability to obtain future
capital, and maintenance of intellectual property rights.
Additional information on risks facing Microbot Medical can be
found under the heading “Risk Factors” in Microbot Medical’s
periodic reports filed with the Securities and Exchange Commission
(SEC), which are available on the SEC’s web site at www.sec.gov.
Microbot Medical disclaims any intent or obligation to update these
forward-looking statements, except as required by law.
Investor Contact:
Michael Polyviou EVC Group mpolyviou@evcgroup.com
732-933-2754
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Apr 2023 to Apr 2024